Clinical Trial Update: Open Label Study to Assess Efficacy and Safety of the Fully Human Anti-TNF-Alpha Monoclonal Antibody Adalimumab

View source ↗

Summary

Adalimumab has received marketing approval for rheumatoid arthritis following an open-label efficacy and safety assessment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Humira (adalimumab)

Snippet

Sponsor: Abbott | Conditions: Rheumatoid Arthritis | Status: APPROVED_FOR_MARKETING